| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00001398 | Aplastic Anemia|Pancytopenia | Drug: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) | Phase 1 | 1993-10-01 | 2008-03-03 |
| NCT00005783 | Hemoglobin SC Disease|Sickle Cell Anemia | Drug: Recombinant-methionyl human stem cell factor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) | Phase 1 | 2000-03-01 | 2008-03-03 |
| NCT00058045 | Lymphoma | Biological: aldesleukin|Biological: recombinant human stem cell factor | Roswell Park Cancer Institute|National Cancer Institute (NCI) | Phase 1 | 2002-08-01 | 2013-01-30 |
| NCT00434239 | Myelodysplasia | Drug: Lenalidomide + Ancestim | Peter MacCallum Cancer Centre, Australia|Celgene Corporation | Early Phase 1 | 2007-02-01 | 2013-01-08 |
| NCT00005993 | Breast Cancer|Lymphoma | Drug: aldesleukin|Drug: filgrastim|Drug: recombinant human stem cell factor|Procedure: peripheral blood stem cell transplantation | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) | Phase 1 | 1999-05-01 | 2012-10-09 |
| NCT01016795 | Malignant Lymphoma | Drug: r-metHuSCF and Filgrastim|Drug: r-metHuSCF and Filgrastim|Drug: Chemotherapy plus Filgrastim | Aalborg Universitetshospital|Herlev Hospital|Rigshospitalet, Denmark|Helsinki University Central Hospital|Turku University Hospital|University Hospital, Linkoeping|Ume University|Oslo University Hospital|Nordic Lymphoma Group|Amgen | Phase 2 | 1999-01-01 | 2015-06-24 |
| NCT00001750 | Multiple Myeloma | Drug: Stemgen | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) | Phase 2 | 1998-09-01 | 2008-03-03 |
| NCT02553304 | Chronic Lymphocytic Leukemia (CLL) | | National Health Research Institutes, Taiwan | | 2015-09-01 | 2016-01-13 |
| NCT00154466 | Myocardial Infarction | Behavioral: cardiac rehabilitation | National Taiwan University Hospital | | 2004-07-01 | 2014-05-25 |
| NCT00001356 | Mastocytosis | | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) | | 1993-05-01 | 2008-03-03 |
| NCT00216112 | Ovarian Cancer | Drug: Imatinib Mesylate|Drug: Docetaxel | Daniela Matei, MD|Novartis Pharmaceuticals|Sanofi|Walther Cancer Institute|Hoosier Cancer Research Network | Phase 2 | 2003-12-01 | 2016-02-17 |
| NCT02461849 | Advanced, Refractory Cancer | Drug: Imatinib | Samsung Medical Center | Phase 2 | 2014-04-04 | 2017-02-15 |
| NCT01440959 | Gastrointestinal Stromal Tumors | Drug: dovitinib | Asan Medical Center | Phase 2 | 2011-09-01 | 2014-01-13 |
| NCT01563822 | Intra-cytoplasmic Sperm Injection Outcome | Biological: Follicular fluid | Nawara Mohamed Hashish|Kasr El Aini Hospital | Phase 1 | 2011-12-01 | 2012-10-06 |
| NCT00731744 | Normal Full-Term Deliveries | Procedure: Normal full-term deliveries | National Taiwan University Hospital | | 2007-01-01 | 2008-08-08 |
| NCT01222143 | Acute Myeloid Leukemia | Drug: NOVE-HiDAC|Drug: Nilotinib | University Health Network, Toronto|Novartis Pharmaceuticals | Phase 1|Phase 2 | 2010-10-01 | 2015-06-19 |
| NCT02145897 | Critical Limb Ischemia | Biological: Autologous Stromal Vascular Fraction (SVF)|Biological: Autologous Adipose Derieved MSCs|Other: Control | Kasiak Research Pvt. Ltd. | Phase 1|Phase 2 | 2014-08-01 | 2014-05-20 |
| NCT01172548 | Gastrointestinal Stromal Tumors | Drug: imatinib mesylate | Novartis Pharmaceuticals|Novartis | Phase 2 | 2008-08-01 | 2017-02-24 |
| NCT01624701 | Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Lymphoma|Myeloma | Other: Ex vivo expanded cord blood cells | Singapore General Hospital|Whitehead Institute for Biomedical Research|Blood Services Group, Health Sciences Authority of Singapore | Phase 1|Phase 2 | 2012-03-01 | 2015-11-26 |
| NCT02148367 | Traumatic Brain Injury | Drug: Erythropoietin | Uniformed Services University of the Health Sciences|National Institutes of Health (NIH) | Phase 2 | 2014-09-01 | 2015-12-30 |
| NCT00003957 | Lymphoma | Biological: filgrastim|Biological: recombinant human stem cell factor|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Drug: mitoxantrone hydrochloride|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation | Fox Chase Cancer Center|National Cancer Institute (NCI) | Phase 2 | 1998-12-01 | 2013-04-16 |
| NCT03033953 | Healthy|Young|Elderly | Dietary Supplement: Native whey|Dietary Supplement: Milk|Other: Strength training | Norwegian School of Sport Sciences|Tine|The Research Council of Norway | | 2014-08-01 | 2017-01-24 |
| NCT00001760 | Atopic Dermatitis|Healthy|Mastocytosis | | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) | | 1998-01-01 | 2007-12-12 |
| NCT00457743 | Gastrointestinal Stromal Tumors | Drug: Sunitinib malate (SU011248) | Pfizer | Phase 1|Phase 2 | 2005-01-01 | 2009-10-02 |
| NCT00569946 | Carcinoma, Renal Cell | Drug: AG-013736 | Pfizer | Phase 2 | 2007-12-01 | 2014-07-16 |
